Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19
Kosinsky Y, Peskov K, Stanski DR, Wetmore D, Vinetz J. Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19. Microbiology Spectrum 2022, 10: e02167-21. PMID: 35412356, PMCID: PMC9047529, DOI: 10.1128/spectrum.02167-21.Peer-Reviewed Original ResearchMeSH KeywordsClinical Studies as TopicCOVID-19 Drug TreatmentEstersGuanidinesHumansSARS-CoV-2Serine ProteasesSerine Proteinase InhibitorsSpike Glycoprotein, CoronavirusConceptsFOY-251SARS-CoV-2 cell entryCamostat mesylateInhibition of TMPRSS2Viral loadClinical trialsCOVID-19Viral entrySerine protease inhibitorSpike proteinCell entryMultiple clinical trialsPharmacokinetic-pharmacodynamic modelSARS-CoV-2 viral entryPK/PDSARS-CoV-2Protease inhibitorsOne-compartmentCell surface serine proteaseViral entry inhibitionTMPRSS2 inhibitionViral surface spike proteinsAcute exacerbationSemi-mechanistic pharmacokinetic-pharmacodynamic modelsSARS-CoV-2 coronavirus